CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Avastin for Malignant Pleural Mesothelioma – Details

Project Number PC0100-000
Brand Name Avastin
Generic Name Bevacizumab
Strength 100 mg and 400 mg vials
Tumour Type Lung
Indication Malignant Pleural Mesothelioma
Funding Request In combination with pemetrexed and cisplatin or carboplatin (for cisplatin ineligible patients), for first-line treatment in patients with unresectable malignant pleural mesothelioma
Review Status Withdrawn
Pre Noc Submission Yes
NOC Date N/A
Manufacturer Hoffmann-La Roche Limited
Sponsor Hoffmann-La Roche Limited
Clarification Hoffmann-La Roche Limited requested a voluntary withdrawal of the pCODR 10100 Bevacizumab (Avastin) MPM Submission. As per pCODR Procedures B3.1.6.2 b), the pCODR Provincial Advisory Group has agreed to the request to withdraw and decided to not continue the review as a PAG Submission.
Submission Date December 16, 2016
Submission Deemed Complete December 23, 2016
Submission Type Initial
Prioritization Requested Requested and Not Granted
Stakeholder Input Deadline ‡ January 9, 2017
Check-point meeting February 27, 2017
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.